PPARA and primary biliary cholangitis: Recently, a randomized, placebo-controlled FITCH trial clearly showed the beneficial effect of the PPAR agonist bezafibrate (400 mg/day) on moderate to severe cholestasis-associated pruritus in PSC and PBC [222].